test,value,rest
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
"IRON, TOTAL",104,50-180 mcg/dL
IRON BINDING CAPACITY,469H250-425,mcg/dL
% SATURATION,22,20-48 % (calc)
FERRITIN,545H38-380,ng/mL
"CHOLESTEROL, TOTAL",231H<200,mg/dL
HDL CHOLESTEROL,62,> OR = 40 mg/dL
TRIGLYCERIDES,226H<150,mg/dL
Jacobson et al. J. of Clin. Lipidol.,2015;9:129-169.,
LDL-CHOLESTEROL,133Hmg/dL,(calc)
with > or =,2,CHD risk factors.
Martin SS et al. JAMA.,2013;310(19):,2061-2068
CHOL/HDLC RATIO,3.7,<5.0 (calc)
NON HDL CHOLESTEROL,169H<130,mg/dL (calc)
For patients with diabetes plus,1,major ASCVD risk
"factor, treating to a non-HDL-C goal of",<100,mg/dL
(LDL-C of,<70,mg/dL) is considered a therapeutic
GGT,38,3-95 U/L
URIC ACID,6.0,4.0-8.0 mg/dL
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
Therapeutic target for gout patients:,<6.0,mg/dL
GLUCOSE,96,65-99 mg/dL
UREA NITROGEN (BUN),24,7-25 mg/dL
CREATININE,1.42H0.70-1.30,mg/dL
EGFR,60,> OR = 60 mL/min/1.
BUN/CREATININE RATIO,17,6-22 (calc)
SODIUM,142,135-146 mmol/L
POTASSIUM,3.8,3.5-5.3 mmol/L
CHLORIDE,99,98-110 mmol/L
CARBON DIOXIDE,22,20-32 mmol/L
CALCIUM,10.1,8.6-10.3 mg/dL
"PROTEIN, TOTAL",7.8,6.1-8.1 g/dL
ALBUMIN,4.8,3.6-5.1 g/dL
GLOBULIN,3.0,1.9-3.7 g/dL (calc)
ALBUMIN/GLOBULIN RATIO,1.6,1.0-2.5 (calc)
"BILIRUBIN, TOTAL",0.7,0.2-1.2 mg/dL
ALKALINE PHOSPHATASE,44,35-144 U/L
AST,78H10-35,U/L
ALT,71H9-46,U/L
"ALBUMIN, URINE",0.6,See Note: mg/dL
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
specimens collected within a,3-6,month period be
APOLIPOPROTEIN,B,109Hmg/dL
Moderate,90-129,
High > or =,130,
A desirable treatment target may be,<80,mg/dL or lower
diabetes with,>1,"risk factors, Stage 3 or greater CKD with"
"and ACC/AHA recommendations (Grundy SM, et al.",2019.,
LEPTIN,3.2,ng/mL
Adult Lean Subjects,(18-71,years) with BMI range
of,18-25:,
Adult Subjects,(19-60,years) with BMI range
of,25-30:,
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
METHYLMALONIC ACID,139,55-335 nmol/L
of MMA to succinic acid requires vitamin,B12,
also used for assessing functional vitamin,B12,deficiency.
Vitamin,B12,"is essential for fetal neurodevelopment,"
vitamin,B12,deficiency may be associated with adverse
"MMA, First trimester",(<13,wks gestation): 58-167 nmol/L
"MMA, Second trimester",(13-23,wks gestation): 63-241 nmol/L
SPECIFIC GRAVITY,1.023,1.001-1.035
PH,6.0,5.0-8.0
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
WBC,NONE,SEEN < OR = 5 /HPF
RBC,NONE,SEEN < OR = 2 /HPF
SQUAMOUS EPITHELIAL CELLS,NONE,SEEN < OR = 5 /HPF
WHITE BLOOD CELL COUNT,6.3,3.8-10.8 Thousand
RED BLOOD CELL COUNT,5.49,4.20-5.80 Million/uL
HEMOGLOBIN,16.3,13.2-17.1 g/dL
HEMATOCRIT,49.4,39.4-51.1 %
MCV,90.0,81.4-101.7 fL
MCH,29.7,27.0-33.0 pg
MCHC,33.0,31.6-35.4 g/dL
value (in the range of,30,to 32 g/dL) is most likely
RDW,14.8,11.0-15.0 %
PLATELET COUNT,161,140-400 Thousand
MPV,11.5,7.5-12.5 fL
ABSOLUTE NEUTROPHILS,2753,1500-7800 cells/uL
ABSOLUTE LYMPHOCYTES,2596,850-3900 cells/uL
ABSOLUTE MONOCYTES,617,200-950 cells/uL
ABSOLUTE EOSINOPHILS,296,15-500 cells/uL
ABSOLUTE BASOPHILS,38,0-200 cells/uL
NEUTROPHILS,43.7,%
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
LYMPHOCYTES,41.2,%
MONOCYTES,9.8,%
EOSINOPHILS,4.7,%
BASOPHILS,0.6,%
presence of up to approximately,150,autoantibodies in
ANA TITER,1:80Htiter,
ANA TITER,1:40Htiter,
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
RHEUMATOID FACTOR,11,<14 IU/mL
HS CRP,1.7,mg/L
Jellinger PS et al. Endocr,Pract.2017;23(Suppl,2):1-87.
For ages,>17,Years:
Consider retesting in,1,to 2 weeks to
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
"CORTISOL, TOTAL, LC/MS",21.3,mcg/dL
Peak,>20.0,mcg/dL
Peak,>16.0,mcg/dL after IM injection
WHEAT,(F4),IGG 15.0H<2.0 mcg/mL
TOMATO,(F25),IGG 6.0H<2.0 mcg/mL
EGG WHITE,(F1),IGG 29.3H<2.0 mcg/mL
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
CASEIN,(F78),IGG 10.7H<2.0 mcg/mL
MAIZE/CORN,(F8),IGG 8.9H<2.0 mcg/mL
YEAST,(F45),IGG 3.9H<2.0 mcg/mL
PEANUT,(F13),IGG 7.5H<2.0 mcg/mL
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
SOYBEAN,(F14),IGG 10.3H<2.0 mcg/mL
CODFISH,(F3),IGG <2.0 <2.0 mcg/mL
CACAO (CHOCOLATE),(F93),IGG 2.8H<2.0 mcg/mL
COFFEE,(F221),IGG 2.9H<2.0 mcg/mL
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
LIPOPROTEIN (a),<10,<75 nmol/L
THYROGLOBULIN ANTIBODIES,<1,< or = 1 IU/mL
HOMOCYSTEINE,10.1,< or = 15.2 umol/L
folate or vitamin,B12.,Testing for methylmalonic acid
"Selhub J, et al., Ann Intern Med.",1999;131(5):331-9.,
DHEA SULFATE,204,61-442 mcg/dL
FSH,9.0,1.4-12.8 mIU/mL
INSULIN,15.4,uIU/mL
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
High,>18.4,
in,2022.,
LH,5.6,1.5-9.3 mIU/mL
PROLACTIN,11.7,2.0-18.0 ng/mL
TSH,4.22,0.40-4.50 mIU/L
ESTRADIOL,62H<,OR = 39 pg/mL
(order code,30289).,
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
VITAMIN,"D,25-OH,TOTAL,IA",67 30-100 ng/mL
Vitamin D Status,25-OH,Vitamin D:
Deficiency:,<20,ng/mL
Insufficiency:,20,- 29 ng/mL
For,25-OH,Vitamin D testing on patients on
of,D2,"and D3 fractions is required, the QuestAssureD(TM)"
code,92888,(patients >2yrs).
See Note,1,
"PSA, TOTAL",1.3,< OR = 4.0 ng/mL
"PSA, FREE",0.4,ng/mL
"PSA, % FREE",31,>25 % (calc)
>or,=26,8
< or =,25,85 19
< or =,30,93 9
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
established in patients with total PSA below,2.6,ng/mL
(+)In men with PSA above,10,"ng/mL, prostate cancer risk is"
The test result will be approximately,20%,higher
AMYLASE,78,21-101 U/L
HEMOGLOBIN,A1c,5.6 <5.7 %
> or,=6.5%,Consistent with diabetes
hemoglobin,A1c,for diagnosis of diabetes in children.
"guidelines, hemoglobin",A1c,<7.0% represents optimal
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
LIPASE,29,7-60 U/L
LEAD (VENOUS),<1.0,<3.5 mcg/dL
Blood lead levels above,3.5,mcg/dL have been associated
See Note,2,
Note,1,
Note,2,
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
"MAGNESIUM, RBC",5.2,4.0-6.4 mg/dL
Lewisville TX,75067,
"TESTOSTERONE, TOTAL, MS",945,250-1100 ng/dL
"TESTOSTERONE, FREE",159.9H35.0-155.0,pg/mL
Lewisville TX,75067,
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
EPA+DPA+DHA,6.9,>5.4 % by wt
Moderate:,3.8-5.4,
High:,<=3.7,
Increasing blood levels of long-chain,n-3,fatty acids
death,(1).,Based on the top (75th percentile) and bottom
> or =,5.5%,by wt defines a population at optimal relative
"risk,",3.8-5.4%,by wt defines a population at moderate
"relative risk, and < or =",3.7%,by wt defines a population
consumption of fish oils is limited to,3,g/day or less of
by about,7-10%,within 2 to 3 weeks.
(Reference:,1-Albert,et al. NEJM. 2002;346: 1113-1118).
ARACHIDONIC ACID/EPA RATIO,7.3,3.7-40.7
EPA,1.5,0.2-2.3 % by wt
DPA,1.3,0.8-1.8 % by wt
DHA,4.1,1.4-5.1 % by wt
ARACHIDONIC ACID,11,8.6-15.6 % by wt
LINOLEIC ACID,16.1L18.6-29.5,% by wt
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
Lewisville TX,75067,
"MERCURY, BLOOD",<5,<11 mcg/L
Lewisville TX,75067,
ZINC,93,60-130 mcg/dL
Lewisville TX,75067,
LDL PARTICLE NUMBER,1297H<1138,nmol/L
LDL SMALL,311H<142,nmol/L
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
Range:,115,to 386 nmol/L.
LDL MEDIUM,283H<215,nmol/L
Range:,121,to 397 nmol/L.
HDL LARGE,5705L>6729,nmol/L
LDL PATTERN BAA Pattern,Z4M,
LDL PEAK SIZE,213.9L>222.9,Angstrom
to,http://education.QuestDiagnostics.com/faq/FAQ134,(This
Enhanced PDF Report,DZ800411S-,
Jeffrey Zavaleta Quest Result,12/07/2025,
Floor,14,
Requisition:,0154717,
Lab Ref #:,2506661,
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267 MAIL992
"AUSTIN, TX",78701-3263,
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
"IRON, TOTAL",104,50-180 mcg/dL
IRON BINDING CAPACITY,469,H 250-425 mcg/dL (calc)
% SATURATION,22,20-48 % (calc)
FERRITIN,545,H 38-380 ng/mL
WHEAT,(F4),IGG 15.0 H <2.0 mcg/mL
TOMATO,(F25),IGG 6.0 H <2.0 mcg/mL
EGG WHITE,(F1),IGG 29.3 H <2.0 mcg/mL
CASEIN,(F78),IGG 10.7 H <2.0 mcg/mL
MAIZE/CORN,(F8),IGG 8.9 H <2.0 mcg/mL
PAGE,1,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
YEAST,(F45),IGG 3.9 H <2.0 mcg/mL
PEANUT,(F13),IGG 7.5 H <2.0 mcg/mL
SOYBEAN,(F14),IGG 10.3 H <2.0 mcg/mL
CODFISH,(F3),IGG <2.0 <2.0 mcg/mL
CACAO (CHOCOLATE),(F93),
PAGE,2,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
IGG,2.8,H <2.0 mcg/mL
COFFEE,(F221),IGG 2.9 H <2.0 mcg/mL
"ALBUMIN, URINE",0.6,mg/dL
specimens collected within a,3-6,month period be
"CHOLESTEROL, TOTAL",231,H <200 mg/dL
HDL CHOLESTEROL,62,> OR = 40 mg/dL
TRIGLYCERIDES,226,H <150 mg/dL
Jacobson et al. J. of Clin. Lipidol.,2015;9:129-169.,
LDL-CHOLESTEROL,133,H mg/dL (calc)
PAGE,3,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
with > or =,2,CHD risk factors.
Martin SS et al. JAMA.,2013;310(19):,2061-2068
CHOL/HDLC RATIO,3.7,<5.0 (calc)
NON HDL CHOLESTEROL,169,H <130 mg/dL (calc)
For patients with diabetes plus,1,major ASCVD risk
"factor, treating to a non-HDL-C goal of",<100,mg/dL
(LDL-C of,<70,mg/dL) is considered a therapeutic
HS CRP,1.7,mg/L
Jellinger PS et al. Endocr,Pract.2017;23(Suppl,2):1-87.
For ages,>17,Years:
Consider retesting in,1,to 2 weeks to
HOMOCYSTEINE,10.1,< or = 15.2 umol/L
folate or vitamin,B12.,Testing for methylmalonic acid
"Selhub J, et al., Ann Intern Med.",1999;131(5):331-9.,
APOLIPOPROTEIN,B,109 H mg/dL
Moderate,90-129,
High > or =,130,
A desirable treatment target may be,<80,mg/dL or lower
PAGE,4,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
diabetes with,>1,"risk factors, Stage 3 or greater CKD with"
"and ACC/AHA recommendations (Grundy SM, et al.",2019.,
GLUCOSE,96,65-99 mg/dL
UREA NITROGEN (BUN),24,7-25 mg/dL
CREATININE,1.42,H 0.70-1.30 mg/dL
EGFR,60,> OR = 60 mL/min/1.73m2
BUN/CREATININE RATIO,17,6-22 (calc)
SODIUM,142,135-146 mmol/L
POTASSIUM,3.8,3.5-5.3 mmol/L
CHLORIDE,99,98-110 mmol/L
CARBON DIOXIDE,22,20-32 mmol/L
CALCIUM,10.1,8.6-10.3 mg/dL
"PROTEIN, TOTAL",7.8,6.1-8.1 g/dL
ALBUMIN,4.8,3.6-5.1 g/dL
GLOBULIN,3.0,1.9-3.7 g/dL (calc)
ALBUMIN/GLOBULIN RATIO,1.6,1.0-2.5 (calc)
"BILIRUBIN, TOTAL",0.7,0.2-1.2 mg/dL
ALKALINE PHOSPHATASE,44,35-144 U/L
AST,78,H 10-35 U/L
ALT,71,H 9-46 U/L
HEMOGLOBIN,A1c,5.6 <5.7 %
> or,=6.5%,Consistent with diabetes
hemoglobin,A1c,for diagnosis of diabetes in children.
"guidelines, hemoglobin",A1c,<7.0% represents optimal
URIC ACID,6.0,4.0-8.0 mg/dL
Therapeutic target for gout patients:,<6.0,mg/dL
GGT,38,3-95 U/L
PAGE,5,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
AMYLASE,78,21-101 U/L
LIPASE,29,7-60 U/L
TSH,4.22,0.40-4.50 mIU/L
THYROGLOBULIN ANTIBODIES,<1,< or = 1 IU/mL
ANTIBODIES,5,<9 IU/mL
LEPTIN,3.2,ng/mL
Adult Lean Subjects,(18-71,years) with BMI range
of,18-25:,
Adult Subjects,(19-60,years) with BMI range
of,25-30:,
METHYLMALONIC ACID,139,55-335 nmol/L
of MMA to succinic acid requires vitamin,B12,
also used for assessing functional vitamin,B12,deficiency.
Vitamin,B12,"is essential for fetal neurodevelopment,"
vitamin,B12,deficiency may be associated with adverse
"MMA, First trimester",(<13,wks gestation): 58-167 nmol/L
"MMA, Second trimester",(13-23,wks gestation): 63-241 nmol/L
PAGE,6,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
WHITE BLOOD CELL COUNT,6.3,3.8-10.8 Thousand/uL
RED BLOOD CELL COUNT,5.49,4.20-5.80 Million/uL
HEMOGLOBIN,16.3,13.2-17.1 g/dL
HEMATOCRIT,49.4,39.4-51.1 %
MCV,90.0,81.4-101.7 fL
MCH,29.7,27.0-33.0 pg
MCHC,33.0,31.6-35.4 g/dL
value (in the range of,30,to 32 g/dL) is most likely
RDW,14.8,11.0-15.0 %
PLATELET COUNT,161,140-400 Thousand/uL
MPV,11.5,7.5-12.5 fL
ABSOLUTE NEUTROPHILS,2753,1500-7800 cells/uL
ABSOLUTE LYMPHOCYTES,2596,850-3900 cells/uL
ABSOLUTE MONOCYTES,617,200-950 cells/uL
ABSOLUTE EOSINOPHILS,296,15-500 cells/uL
ABSOLUTE BASOPHILS,38,0-200 cells/uL
NEUTROPHILS,43.7,%
LYMPHOCYTES,41.2,%
MONOCYTES,9.8,%
EOSINOPHILS,4.7,%
BASOPHILS,0.6,%
SPECIFIC GRAVITY,1.023,1.001-1.035
PH,6.0,5.0-8.0
WBC,NONE,SEEN < OR = 5 /HPF
RBC,NONE,SEEN < OR = 2 /HPF
SQUAMOUS EPITHELIAL CELLS,NONE,SEEN < OR = 5 /HPF
RHEUMATOID FACTOR,11,<14 IU/mL
PAGE,7,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
"CORTISOL, TOTAL, LC/MS",21.3,mcg/dL
Peak,>20.0,mcg/dL
Peak,>16.0,mcg/dL after IM injection
LIPOPROTEIN (a),<10,<75 nmol/L
DHEA SULFATE,204,61-442 mcg/dL
FSH,9.0,1.4-12.8 mIU/mL
INSULIN,15.4,uIU/mL
High,>18.4,
in,2022.,
LH,5.6,1.5-9.3 mIU/mL
PROLACTIN,11.7,2.0-18.0 ng/mL
ESTRADIOL,62,H < OR = 39 pg/mL
(order code,30289).,
PAGE,8,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
GLOBULIN,50,10-50 nmol/L
"PSA, TOTAL",1.3,< OR = 4.0 ng/mL
"PSA, FREE",0.4,ng/mL
"PSA, % FREE",31,>25 % (calc)
>or,=26,8
< or =,25,85 19
< or =,30,93 9
established in patients with total PSA below,2.6,ng/mL
(+)In men with PSA above,10,"ng/mL, prostate cancer risk is"
The test result will be approximately,20%,higher
LEAD (VENOUS),<1.0,<3.5 mcg/dL
PAGE,9,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
Blood lead levels above,3.5,mcg/dL have been associated
See Endnote,1,
"MAGNESIUM, RBC",5.2,4.0-6.4 mg/dL
Lewisville TX,75067,
"TESTOSTERONE, FREE",Z3E,
"TESTOSTERONE, TOTAL, MS",945,250-1100 ng/dL
"TESTOSTERONE, FREE",159.9,H 35.0-155.0 pg/mL
PAGE,10,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
Lewisville TX,75067,
"MERCURY, BLOOD",<5,<11 mcg/L
Lewisville TX,75067,
ZINC,93,60-130 mcg/dL
Lewisville TX,75067,
Endnote,1,
PAGE,11,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
VITAMIN,"D,25-OH,TOTAL,IA",67 30-100 ng/mL
Vitamin D Status,25-OH,Vitamin D:
Deficiency:,<20,ng/mL
Insufficiency:,20,- 29 ng/mL
For,25-OH,"Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the"
QuestAssureD(TM),25-OH,"VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs)."
"For additional information, please refer to",http://education.QuestDiagnostics.com/faq/FAQ199,(This link is being provided for informational/ educational
ANA IFA is a first line screen for detecting the presence of up to approximately,150,autoantibodies in various autoimmune diseases. A positive ANA IFA
"For additional information, please refer to",http://education.QuestDiagnostics.com/faq/FAQ177,(This link is being provided for informational/ educational
ANA TITER,1:80,H titer
ANA TITER,1:40,H titer
The presence of mitotic fluorescence was noted on the,HEp-2,"slide. Other reactivities (e.g., anti-mitotic spindle apparatus antigens) may be responsible for"
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
LDL PARTICLE NUMBER,<1138,1138-1409 >1409 nmol/L
LDL SMALL,<142,142-219 >219 nmol/L
LDL MEDIUM,<215,215-301 >301 nmol/L
HDL LARGE,>6729,6729-5353 <5353 nmol/L
LDL PEAK SIZE,>222.9,222.9-217.4 <217.4 Angstrom
EPA,1.5,0.2-2.3 % by wt
DPA,1.3,0.8-1.8 % by wt
DHA,4.1,1.4-5.1 % by wt
ARACHIDONIC ACID,11,8.6-15.6 % by wt
LINOLEIC ACID,16.1,L 18.6-29.5 % by wt
PAGE,14,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
option,1,to arrange a consult with our clinical education team.
PAGE,15,OF 16
Collected:,12/01/2025,/ 08:11 CST
Reported:,12/07/2025,/ 14:54 CSTClient #: 73917267
CLIENT SERVICES:,866.697.8378,SPECIMEN: DZ800411S
HDL LARGE,5705,>6729 nmol/L
LDL MEDIUM,283,<215 nmol/L
LDL PARTICLE NUMBER,1297,<1138 nmol/L
LDL PATTERN,B,A Pattern
LDL PEAK SIZE,213.9,>222.9 Angstrom
LDL SMALL,311,<142 nmol/L
LINOLEIC ACID,16.1,18.6-29.5 % by wt
MDF med fusion,2501,"South State Highway 121,Suite 1100 Lewisville TX 75067 972-966-7300 Ithiel James L. Frame, MD, PhD"
ARACHIDONIC ACID,11,8.6-15.6 % by wt
ARACHIDONIC ACID/EPA RATIO,7.3,3.7-40.7
DHA,4.1,1.4-5.1 % by wt
DPA,1.3,0.8-1.8 % by wt
EPA,1.5,0.2-2.3 % by wt
EPA+DPA+DHA,6.9,>5.4 % by wt
risk categories were established for OmegaCheck: A cut-off of > or =,5.5%,"by wt defines a population at optimal relative risk, 3.8-5.4% by wt defines a population at"
"moderate relative risk, and < or =",3.7%,by wt defines a population at high relative risk of sudden cardiac death. The totality of the scientific evidence demonstrates that
when consumption of fish oils is limited to,3,"g/day or less of EPA and DHA, there is no significant risk for increased bleeding time beyond the normal range. A daily dosage"
of,1,gram of EPA and DHA lowers the circulating triglycerides by about 7-10% within 2 to 3 weeks. (Reference: 1-Albert et al. NEJM. 2002;346: 1113-1118). This test was
"EZQUEST DIAGNOSTICS/NICHOLS SJC,",33608,"ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: IRINA MARAMICA,MD,PHD,MBA, CLIA: 05D0643352"
"IGQUEST DIAGNOSTICS DALLAS LAB,",4770,"REGENT BOULEVARD, IRVING, TX 75063-2445 Laboratory Director: CLARE MCCORMICK-BAW, MD PHD, CLIA: 45D0697943"
PAGE,16,OF 16
